Amarin reported $20.81M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amarin USD 20.81M 13K Dec/2025
AstraZeneca USD 1.55B 44K Jun/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
DBV Technologies USD 235.6M 98.78M Dec/2025
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Novartis USD 1.9B 7.38M Jun/2026